RAC - Charts & Price Action, page-18525

There is still a few basic things the broader RACE team can do to help themselves and improve sentiment among existing shareholders and potentially attract the interest of other shareholders, namely:

- Pete Smith following through with his comments from the AGM regarding his intent to buy RAC shares on-market. If he believes the Triangle Report is credible, what is he waiting for? How cheap does it need to get before he moves?
- Would Pete consider buying a chunk off JC (if he wants to sell more) or alternatively find a soph/insto wanting to take a stake in the company.
- RAC Directors (other than Dr T) exercising options early. The $$ they require to do this is insignificant, so the DCB excuse of 'I can't afford it' should not apply here.

It is going to be a long 5+ months for some investors while the important box ticking goes on behind the scenes to get RC220 approved and clinical trials up and running for H2 - so simple, tangible actions such as the above are important first steps to rebuild shareholder trust after a turbulent 2023.